298 related articles for article (PubMed ID: 22326467)
1. Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis.
Penna A; Laccabue D; Libri I; Giuberti T; Schivazappa S; Alfieri A; Mori C; Canetti D; Lampertico P; Viganò M; Colombo M; Loggi E; Missale G; Ferrari C
J Hepatol; 2012 Jun; 56(6):1239-46. PubMed ID: 22326467
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha.
Rico MA; Quiroga JA; Subirá D; Castañón S; Esteban JM; Pardo M; Carreño V
Hepatology; 2001 Jan; 33(1):295-300. PubMed ID: 11124848
[TBL] [Abstract][Full Text] [Related]
3. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.
Sonneveld MJ; Hansen BE; Piratvisuth T; Jia JD; Zeuzem S; Gane E; Liaw YF; Xie Q; Heathcote EJ; Chan HL; Janssen HL
Hepatology; 2013 Sep; 58(3):872-80. PubMed ID: 23553752
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients.
Chen CH; Lee CM; Hung CH; Wang JH; Hu TH; Changchien CS; Lu SN
J Gastroenterol Hepatol; 2011 Mar; 26(3):461-8. PubMed ID: 21332543
[TBL] [Abstract][Full Text] [Related]
5. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
Buster EH; Hansen BE; Lau GK; Piratvisuth T; Zeuzem S; Steyerberg EW; Janssen HL
Gastroenterology; 2009 Dec; 137(6):2002-9. PubMed ID: 19737568
[TBL] [Abstract][Full Text] [Related]
6. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
[TBL] [Abstract][Full Text] [Related]
7. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B.
Lampertico P; Viganò M; Di Costanzo GG; Sagnelli E; Fasano M; Di Marco V; Boninsegna S; Farci P; Fargion S; Giuberti T; Iannacone C; Regep L; Massetto B; Facchetti F; Colombo M;
Gut; 2013 Feb; 62(2):290-8. PubMed ID: 22859496
[TBL] [Abstract][Full Text] [Related]
8. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
9. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.
Bonino F; Marcellin P; Lau GK; Hadziyannis S; Jin R; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Brunetto MR; Farci P; Popescu M; McCloud P;
Gut; 2007 May; 56(5):699-705. PubMed ID: 17127704
[TBL] [Abstract][Full Text] [Related]
10. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B.
Zhu X; Gong Q; Yu D; Zhang D; Gu L; Han Y; Chen J; Zhang Y; Zhang X
J Clin Virol; 2013 Aug; 57(4):318-22. PubMed ID: 23639294
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study.
Kim BH; Lee YJ; Kim W; Yoon JH; Jung EU; Park SJ; Kim YJ; Lee HS
Scand J Gastroenterol; 2012 Sep; 47(8-9):1048-55. PubMed ID: 22726105
[TBL] [Abstract][Full Text] [Related]
12. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
Tangkijvanich P; Komolmit P; Mahachai V; Sa-nguanmoo P; Theamboonlers A; Poovorawan Y
J Clin Virol; 2009 Oct; 46(2):117-23. PubMed ID: 19651540
[TBL] [Abstract][Full Text] [Related]
13. Interferon therapy of chronic hepatitis B.
Brunetto MR; Bonino F
Intervirology; 2014; 57(3-4):163-70. PubMed ID: 25034484
[TBL] [Abstract][Full Text] [Related]
14. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
Peng CY; Lai HC; Li YF; Su WP; Chuang PH; Kao JT
Aliment Pharmacol Ther; 2012 Feb; 35(4):458-68. PubMed ID: 22225574
[TBL] [Abstract][Full Text] [Related]
15. Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a (40 kda; PEGASYS).
Chan HL; Wong VW; Chim AM; Wong GL; Chan HY; Sung JJ
Antivir Ther; 2008; 13(4):555-62. PubMed ID: 18672534
[TBL] [Abstract][Full Text] [Related]
16. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.
Tseng TC; Yu ML; Liu CJ; Lin CL; Huang YW; Hsu CS; Liu CH; Kuo SF; Pan CJ; Yang SS; Su CW; Chen PJ; Chen DS; Kao JH
Antivir Ther; 2011; 16(5):629-37. PubMed ID: 21817184
[TBL] [Abstract][Full Text] [Related]
17. Response and seroconversion rates among HBeAg-positive chronic HBV Egyptian patients treated with peginterferon alpha 2a (Pegasys), a single-centre experience.
Maklad S; Esmat G; Doss W; Abou-Zeid A; El-Din SS
Arab J Gastroenterol; 2013 Jun; 14(2):73-7. PubMed ID: 23820505
[TBL] [Abstract][Full Text] [Related]
18. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
Takkenberg RB; Jansen L; de Niet A; Zaaijer HL; Weegink CJ; Terpstra V; Dijkgraaf MG; Molenkamp R; Jansen PL; Koot M; Rijckborst V; Janssen HL; Beld MG; Reesink HW
Antivir Ther; 2013; 18(7):895-904. PubMed ID: 23639931
[TBL] [Abstract][Full Text] [Related]
19. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.
Moucari R; Mackiewicz V; Lada O; Ripault MP; Castelnau C; Martinot-Peignoux M; Dauvergne A; Asselah T; Boyer N; Bedossa P; Valla D; Vidaud M; Nicolas-Chanoine MH; Marcellin P
Hepatology; 2009 Apr; 49(4):1151-7. PubMed ID: 19115222
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B.
Rijckborst V; ter Borg MJ; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Raptopoulou-Gigi M; Ormeci N; Zondervan PE; Verhey E; van Vuuren AJ; Hansen BE; Janssen HL;
Am J Gastroenterol; 2010 Aug; 105(8):1762-9. PubMed ID: 20461068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
